Abstract

Clinical global impressions of change (CGICs) are important measures of efficacy in clinical trials. CGIC scales have been used extensively as primary outcome criteria in psychopharmacological trials and in early clinical trials for antidementia drugs (e.g., Schneider and Olin, 1994). CGICs have been reported to be the most sensitive index of change in 14 of 17 dementia trials, when compared to other measures (Lehmann, 1984).